Developing a single-dose, intranasal, live-attenuated vaccine against COVID-19
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
The COVID-19 pandemic continues to spread in the U.S. and around the world. COVI-VAC is a single-dose, intranasal, live attenuated vaccine against COVID-19, generated using Codagenix’s proprietary deoptimization technology.
RSV hospitalizations among adults 65+ no vaccine
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
October 19, 2021
Codagenix Announces Appointment of Two New Members to its Board of Directors
September 22, 2021
Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies
Novel intranasal vaccine candidate shows promise for immunity against COVID-19 and virus variantsFull Story